UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
University of California, Davis
AgonOx, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Medicenna Therapeutics, Inc.
Genocea Biosciences, Inc.
National Cancer Institute (NCI)